Aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia are the two characteristic types of primary aldosteronism. Dysregulation of adrenal cortical cell proliferation contributes to both diseases. We previously demonstrated that APA expressed less dopamine D2 receptor than the respective non-tumor tissue and might contribute to the overproduction of aldosterone. As activation of D2 receptor inhibits the proliferation of various cells, downregulation of D2 receptor in APA may play a role in the tumorigenesis of APA. In this study, we demonstrate that D2 receptor plays a role in angiotensin II (AII)-stimulated adrenal cortical cell proliferation. The D2 receptor agonist, bromocriptine, inhibited AII-stimulated cell proliferation in primary cultures of the normal human adrenal cortex and APA through attenuating AII-induced phosphorylation of PK-stimulated cyclin D1 protein expression and cell proliferation. D2 receptor also inhibited AII-induced ERK1/2 phosphorylation. Our results demonstrate that, in addition to inhibiting aldosterone synthesis/production, D2 receptor exerts an anti-proliferative effect in adrenal cortical and APA cells by attenuating PKCm and ERK phosphorylation. The lower level of expression of D2 receptor in APA may augment cell proliferation and plays a crucial role in the tumorigenesis of APA. Our novel finding suggests a new therapeutic target for primary aldosteronism.
Introduction
There is growing evidence that the prevalence of primary aldosteronism is much higher than previously thought (Rossi et al. 2006) . The two main subtypes of primary aldosteronism are bilateral adrenal hyperplasia and aldosterone-producing adenoma (APA). The pathogenesis of both diseases involves the over-proliferation of adrenal cortical cells. However, the molecular mechanism remains unclear. Although angiotensin II (AII) stimulates aldosterone production through the angiotensin type 1 receptor (AT1R), its effect on the proliferation of the aldosterone-producing cells is controversial (McEwan et al. 1990 , Mazocchi et al. 1997 , Otis et al. 2004 , 2005 . There was no difference in the level of AT1R between APA and the non-tumorous part of the adrenal (Chang et al. 2007) , and a linkage study failed to demonstrate a role of AT1R in the pathogenesis of primary aldosteronism (Torpy & Stratakis 1998) . Recently, we demonstrated that the downregulation of dopamine D2 receptor (DRD2) in APA contributed to the increased CYP11B2 mRNA and aldosterone over-production through enhancing PKCm activation (Chang et al. 2007 ). This finding indicates that the DRD2 plays an important role in the pathogenesis of primary aldosteronism.
Many studies have shown a role of DRD2 in cell proliferation. Activation of DRD2 inhibited proliferation of various cells, such as forebrain neural stem cells, vascular endothelial cells, colon epithelial cells, and lactotrophs (Saiardi et al. 1997 , Gemignani et al. 2005 , Campa et al. 2007 . Transgenic knockout of DRD2 in mice resulted in hyperprolactinemia and prolactinoma (Kelly et al. 1997 , Saiardi et al. 1997 . In human studies polymorphisms of dopamine receptors are associated with the risk of colorectal cancer (Gemignani et al. 2005 ) and lung cancer (Campa et al. 2007) .
The effect of DRD2 on AII-stimulated aldosterone synthesis/secretion of H295R cells, a human adrenal cortical carcinoma cell line, is mediated via inhibition of the phosphorylation of PKCm (Chang et al. 2007 ). PKCm and its mouse homolog PKD, a serine/threonine protein kinase, have been implicated in diverse cell functions including immune response, apoptosis/cell proliferation, and tumor metastasis (Rykx et al. 2003 , Wang 2006 . As activation of D2 receptors may inhibit cell proliferation via inhibition of AII-stimulated phosphorylation of PKCm, we developed the hypothesis that downregulation of D2 receptors in APAs plays a role in their tumorigenesis.
Subjects and methods

Patients and tissue samples
The diagnosis of APA was established by clinical manifestations of primary aldosteronism and confirmed histologically. Adrenal samples were obtained from surgical specimens of 12 APA patients and three patients with renal cell carcinoma without adrenal disease, after obtaining informed consent. Adrenal glands from APA patients were separated into tumor and non-tumor portions after the adrenal medulla was dissected. Nodules surrounding the main tumor were not included in the non-tumor portion. The study was approved by the Ethical Committee of the National Taiwan University Hospital (NCT00173446).
Cell culture
Primary cultured cells from human normal adrenal cortex (NAC) were prepared from surgical specimens of patients who were free from adrenal disease. The primary NAC culture was prepared as described by Liu et al. (1995) . Briefly, small pieces of tissue were washed in Hanks' Balanced Salt Solution and minced in culture medium (DMEM-Ham's F-12 medium containing 10% FCS, 2 mmol/l glutamine (Gibco), 1.25!10 5 IU/l penicillin, and 0.125 g/l streptomycin sulfate (Gibco)). The minced tissues were dissociated with 0.3% collagenase-IA and 20 mg/l deoxyribonuclease-I (Sigma-Aldrich Co.) in culture medium at 37 8C. Digestion was carried out over two 2-h periods. The dispersed cells were washed once with medium and plated on six-well plastic cell culture dishes. The cultures were maintained at 37 8C in humidified 95% air at 5% CO 2 , with replacement of medium every 3 days until the cells achieved subconfluency on days 5-10 of culture. The NAC cells cultured at this stage expressed both DRD2 and AT1R and preserved the physical function to secrete aldosterone after addition of AII. Ten nanomolar AII (Sigma-Aldrich Co.), 1 mmol/l bromocriptine (BMC) (Sigma-Aldrich Co.), and 1 mmol/l raclopride (Racl) (Sigma-Aldrich Co.) were used in all experiments unless otherwise mentioned. All experiments were performed at least in triplicate; for each experiment, the data analyzed was the mean of three measured samples.
Chemicals
AII, BMC, Racl, tetrazole 3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium bromide (MTT), and PD98059 were purchased from Sigma-Aldrich Co. and phospho-PKC-specific antibodies, PKC subtype-specific antibodies, and phospho-MAPK-specific antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA). AT1R (sc1173), P21 (sc817), P27 (sc1641), and P53 (sc71784) were obtained from Santa Cruz Biotechnology, Inc. D2 receptor antibody and its immunizing peptide were from Chemicon (Temecula, CA, USA). Cyclin D1 (NB110-2308) antibody was from Novus Biologicals, Inc. (Littleton, CO, USA).
Immunoblotting
APA and NAC were separated from surgical specimens and solubilized in lysis buffer. For western blots, equal amounts of protein (10 mg for human tissue) were separated on a 10% polyacrylamide gel and were transferred to Immobilon P membranes. Blots were probed with different antibodies, followed by a HRP-conjugated anti-rabbit secondary antibody. Immunoreactive proteins were visualized with enhanced chemiluminescence (Pierce, Rockford, IL, USA).
MTT test
The MTT cell proliferation assay was purchased from the American Tissue Culture Collection (Manassas, VA, USA) and performed according to the manufacturer's instructions. Briefly, NAC or APA cells were incubated in the presence of 0.5 mg/ml MTT reagent for 4-8 h, after which cells were lysed by the addition of one volume of solubilization solution (40% dimethylformamide and 10% SDS, pH 4.0). Absorbance (A) in the wells was read with a microplate reader with a 570 nm cutoff filter. Viable cells metabolizing MTT were quantified at 570 nm by spectrophotometer and then translated into the cell number by normalizing the measurement against the 570 nm absorption of a known number of directly countable viable cells.
Quantitative real-time PCR
Quantitative real-time PCR was carried out in an Applied Biosystems 7900 Real-Time PCR System using TaqMan gene expression assays for AT1R and DRD2 as described in the user manual (assay ID, Hs00258938_m1 and Hs00241436_m1 respectively). GAPDH (assay ID, Hs99999905_m1) was used as an endogenous control in the TaqMan human endogenous control plate (Applied Biosystems; Volpe et al. 1997) . Cycle to threshold (Ct) was recorded for statistical analysis. Sample dilutions contained 100 ng template cDNA. All samples were tested in a total volume of 20 ml in triplicate.
Short hairpin RNA (shRNA) for PKCm
The sense strand for synthesis of shRNA targeting PKCm was CCAGAGCACATAACGAAGTTT. The control plasmid expressing an shRNA against EGFP was purchased from Open Biosystems, Inc. (Huntsville, AL, USA). Lentiviruses carrying the target nucleotides were generated by cotransfecting 9 mg lentiviral vector (Plko1), 4.5 mg pHCMV-G (envelope system: VSV-G), and 6.75mg of pCMVDR8.2 (packaging vector: env, tat, rev, vpr, vpu, vif, and nef) into 293T cells using calcium phosphate reagent (2! BBS 750 ml, 2.5 M CaCl 2 75 ml, and H 2 O 750 ml) (Dull et al. 1998) . Supernatants were collected 48 and 72 h after transfection, filtered through a 0.45 mm membrane (Amicon Ultra-15 100K, Millipore, Billerica, MA, USA), centrifuged at 4000 g for 30 min at 4 8C, and used to directly infect NAC. The level of PKCm was semi-quantified by SDS-PAGE and immunoblotting with a PKCm-specific antibody. The experiments were carried out 48 h after infection.
Bromodeoxyuridine assay
Cell proliferation was determined by bromodeoxyuridine (BrdU) incorporation analysis. NAC cells were plated in 96-well plates (100 cells/well, counted with a hemocytometer). After incubation for 12 h, BrdU was added to the medium for 2 h. (HTS01, Calbiochem EMD Chemicals, Inc., Billerica, CA, USA). Plates were analyzed using a fluorometer at 320 nm excitation and 460 nm emission.
Cell apoptosis assay DNA fragmentation was detected by an ELISA specific for nucleosome-associated cytosolic DNA. Apoptosis ELISA was performed using the Roche Cell Death Detection ELISA Kit (Roche Diagnostics). This assay is based on the sandwich-enzyme immunoassay principle using mouse MABs directed against DNA and histones respectively. This technique allows the specific determination of mononucleosomes and oligonucleosomes in the cytoplasmic fraction of the cell. Cell lysates isolated as described above were used for ELISA. Sample absorbance was read with a spectrophotometer at a wavelength of 405 nm.
Statistical analysis
Statistical analysis was performed with the MannWhitney U test using the Stat View Software Package (Abacus Concepts, Inc., Berkeley, CA, USA). Statistical significance was accepted for P!0.05. All the statistical analyses were aided by the advice of the statistics specialist of the Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine.
Results
DRD2 activation attenuated AII-induced cell proliferation
Three cell populations of APA and three clones of NAC were obtained from APA and renal cell carcinoma patients respectively. The viability of the cells was assayed using the MTT test at 4, 8, 12, 24, and 48 h after subculture with 2000 cells in each well of 96-well plates. The increase in the number of viable cells after 24 h is illustrated in Fig. 1a . Under all conditions, treated or untreated, the cell numbers for APA were greater than those for NAC (P!0.01). After 24-h culture, the increased cell number for APA was 30% more than that for NAC cells. AII doubled the cell numbers of both of APA and NAC, but the difference remained 30%. Treatment with DRD2 agonist (BMC) attenuated the AII-stimulated viable cell number of both NAC and APA (P!0.005). The BMC effect could be partially reversed by DRD2 antagonist (Racl) for both NAC and APA, 12 and 23% respectively (P!0.05). Our previous study showed that DRD2 was expressed much less in APA than in the respective non-tumorous adrenal cortex. Whether DRD2 has a role in the regulation of the proliferative adrenal cortical cells should be clarified. Treatment with BMC (1 mmol/l) attenuated the AIIinduced increase in cell number (Fig. 1a and b) but did not alter the basic growth rates for either NAC or APA cells. This attenuating effect of BMC was more obvious in APA than in NAC cells and was partially reversed by treatment with Racl ( Fig. 1a and b) . The rate of cell proliferation decelerated when cells became confluent (Fig. 1b) .
In order to understand whether the increase in the number of viable cells stimulated by AII resulted from increased cell proliferation or decreased cell death, BrdU incorporation was performed to measure the rate of DNA synthesis, which is known to parallel the rate of cell division. Because the significant differences in the numbers of the viable cells were observed by 24 h after treatment, the cell division rates were measured at 12 h. Treatment with AII significantly enhanced BrdU incorporation of NAC cells; this effect was attenuated by BMC and was partially reversed by adding Racl (Fig. 1c) . On the other hand, in the apoptosis experiments, the accumulations of BrdU-incorporated DNA fragments in cell extracts at 24 h were not affected by the experimental conditions (Fig. 1d) ; additionally, no differences were observed in the supernatants (data not shown). These results indicate that the effect of BMC on the AII-stimulated increase in cell viability was due to the inhibition of cell proliferation but not the induction of cell apoptosis.
DRD2 level in APA, non-tumorous tissue, and in the NAC Consistent with our previous study, the level of DRD2 in APA was much lower than in the respective non-tumorous adrenal cortex or NAC. The levels of AT1R were not different among the three different tissue samples (Fig. 2a) . The mRNA expression of DRD2 and AT1R in these three different samples paralleled the findings from western blotting, namely that DRD2 mRNA level was downregulated in APA, and no difference in AT1R mRNA expression was observed, in comparison with the non-tumor portion and NAC (Fig. 2b) .
Effect of DRD2 on PKCm phosphorylation and cell proliferation
As demonstrated in our previous study, APA expressed more abundant phosphorylated PKCm than the non-tumor portion or NAC (P!0.05; Fig. 3a) . The levels of total PKCm, total PKCa, total PKCbII, and phosphorylated PKCa/bII were not different among three types of tissue samples however. In primary cultured cells of NAC, AII increased the phosphorylation of PKCm (Ser916), PKCm (Ser744/748), PKCa/bII, and PKC3, but not PKCq or PKCl. BMC treatment attenuated only the AII-induced PKCm (Ser916) phosphorylation, which was reversed by adding Racl (Fig. 3b) . Depletion of PKCm protein expression in NAC via transfection of targeted shRNA reduced the level of AII-stimulated cell proliferation by over 50% (Fig. 3c ).
DRD2 and MAPK phosphorylation
There was a higher level of phospho-ERK in APA than in non-tumorous tissue and NAC; however, there was no difference in the levels of phospho-JNK and phospho-p38 among these tissue samples (Fig. 4a) .
To investigate whether the anti-proliferative effect of DRD2 is mediated by modification of MAPK activation, the effects of BMC on the phosphorylation of ERK1/2, JNK, and p38 were studied. AII stimulated the phosphorylation of these three molecules, but only the phosphorylation of ERK1/2 was attenuated by BMC (Fig. 4b) , more than 30%. PD98059, an inhibitor of ERK phosphorylation, dose dependently inhibited AII-stimulated cell proliferation (Fig. 4c) . This result indicates that the inhibitory effect of DRD2 on AII-induced proliferation of NAC cells was mostly due to the attenuation of ERK phosphorylation. Depletion of PKCm reduced AIIstimulated ERK phosphorylation by more than 50% (Fig. 4d) .
Cyclin D1 as a target for AII-stimulated cell cycle progression AII treatment increased cyclin D1 protein expression in NAC cells, and BMC significantly attenuated it; this effect was reversed by adding Racl (Fig. 5a ). Depletion of PKCm by infection with lentiviruses PKCm shRNA reduced protein expression of AII-induced cyclin D1 by 30% (Fig. 5b) . Inhibition of ERK phosphorylation by PD98059 also decreased AII-stimulated cyclin D1 protein expression (Fig. 5c ).
Discussion
PKCm (PKD) has been proven to play a role in AII-induced aldosterone production (Romero et al. 2006 , Shapiroa et al. 2010 . In a previous study, we demonstrated that DRD2 inhibits AII-stimulated aldosterone synthesis/ secretion through attenuation of PKCm phosphorylation (Chang et al. 2007) . In this study, we further found that DRD2 inhibited AII-stimulated proliferation of NAC and APA cells, and that phosphorylation of PKCm was responsible for the signaling mechanism. In fact, we cannot separate the zona fasciculata (ZF) cells from zona glomerulosa (ZG) cells completely as many previous reports. It is highly possible that some of our cultured cells were ZG cells and some were ZF cells. However, there were over 70% CD56-positive cells in our primary cultured NAC and APA cells. It has been noted that ZG cells rather than ZF cells expressed CD56 (Caroccia et al. 2010) . In addition, the mRNA expressions of CYP11B2 over CYP11B1 were about 6.86 and 8.78 in our primary cultured NAC and APA cells respectively, indicating that most of the cultured cells were ZG cells. In addition, a previous report has shown that AII stimulated cell proliferation of ZG cells rather than ZF or zona reticularis (ZR) cells (Mazocchi et al. 1997) . Our experiments demonstrated that a DRD2 agonist did not alter the basal proliferation rate but inhibited AII-stimulated proliferation of adrenal cortical cells (Fig. 1b) . Therefore, the inhibitory effect of DRD2 on the cultured adrenal cortical cells should be limited to the AII-stimulated proliferation of ZG cells rather than the ZF cells.
AII-stimulated PKC translocation contributes to the proliferation of cultured human breast epithelial cells (Greco et al. 2002) . AII also stimulates the proliferation of choriocarcinoma cells through the AT1R and its downstream signals, including PKC and MAPK (Ino et al. 2003) . The mitogenic response of adrenal glomerulosa cells to AII is mediated via AT1R activation (McEwan et al. 1990 , Tian et al. 1995 . However, studies analyzing the expression of AT1R in APA have not shown significant differences in AT1R mRNA levels in comparison with non-tumorous tissue (Kitamura et al. 1998 , Chang et al. 2007 ). In our previous study, we found that AII-stimulated PKCa/bII, PKC3, and PKCm phosphorylation and translocation to membrane in human adrenal cortical cells and DRD2 activation only attenuated AII-stimulated PKCm phosphorylation and translocation to membrane (Chang et al. 2007) . Therefore, the tumorigenesis of APA can be partially attributed to the loss of DRD2 inhibitory tone under concomitant stimulation by AII. An interactive balance between DRD2 and AII signaling appears to underlie the regulation of adrenal cortical cell proliferation.
In this study, we demonstrated that the inhibitory effect of DRD2 on adrenal cortical cell proliferation was mediated by attenuation of PKCm phosphorylation. PKCm is involved in many physiological functions including cell proliferation, migration, protein transport, survival, and apoptosis (Wang 2006) . Over-expression of PKD1, the mouse homolog of PKCm, has been noted in mouse skin carcinoma (Iaccarino et al. 2002) as well as in basal cell carcinoma and psoriatic skin lesions (Ristich et al. 2006) . Inhibition of PKCm by Go6976 decreased the proliferation of primary mouse epidermal keratinocytes (Hausser et al. 2001) . VEGF-induced angiogenesis of primary human umbilical vein endothelial cells has been shown to require PKCm phosphorylation (Rennecke et al. 1999) . In Swiss 3T3 cells, over-expression of PKCm potentiates DNA synthesis and cell growth induced by bombesin and vasopressin (Zhukova et al. 2001 , Sinnett-Smith et al. 2004 . Our study showed a greater level of phosphorylated PKCm in tumor areas of APA than in non-tumor areas or in the NAC. The inhibition of AIIstimulated cell proliferation by depletion of PKCm indicates the involvement of PKCm in the mitogenesis of adrenal cortical cells. Therefore, the decreased DRD2 level in APA may augment AII-stimulated PKCm phosphorylation and in turn contribute to APA tumorigenesis. ERK1/2 is a signaling molecule that responds to several mitogenic stimuli (Werry et al. 2006 , Katz & Yarden 2007 .
We demonstrated that AII stimulated the phosphorylation of ERK1/2, JNK, and p38 in human adrenal cortical cells, but only ERK1/2 was modulated by DRD2. The effects of DRD2 on MAPK/ERK activation are controversial. In mouse endothelial cells, dopamine inhibits VEGF-induced phosphorylation of VEGFR2, MAPK, and focal adhesion kinase (Sarkar et al. 2004) . However, Iaccarino et al. (2002) observed increased phosphorylation of ERK1/2 in lactotroph cells at 15 min after addition of BMC, followed by a return to the baseline levels at 16 h. Over-expression of the short variant of DRD2 in mice led to the activation of MAPK and levels of phosphorylated ERKs decreased in DRD2-null mice (Asa et al. 1999) . Despite the opposite effect of MAPK activation, ligand activation of DRD2 results in decreased proliferation of lactotroph cells and leads to pituitary hypoplasia (Iaccarino et al. 2002) . In addition, ablation of DRD2 resulted in hyperprolactinemia and prolactinomas (Asa et al. 1999) . The current study showed that a D2 agonist selectively attenuated AII-stimulated phosphorylation of ERK1/2 but not JNK and p38 in human adrenal cortical cells. In comparison with NAC, APA showed downregulation of DRD2 that was accompanied by the elevated phosphorylation of PKCm and ERK1/2. Therefore, loss of the inhibitory effect of DRD2 on AII-stimulated PKCm and ERK1/2 phosphorylation may play a role in the tumorigenesis of APA. There is evidence for the relationship between PKCm and ERK1/2. Transient expression of constitutively active PKCm led to activation of Raf-1 kinase and phosphorylation of ERK1 but not of JNK and p38 MAPKs (Hausser et al. 2001) . PKCm may also mediate endothelial proliferation and ERK activation induced by vascular endothelial growth factor (Wong & Jin 2005) . PKCm upregulates Ras activity and ERK1/2 signaling by phosphorylating Ras-binding protein RIN1 to release Ras for subsequent activation in the Raf-MEK-ERK pathway (Lint et al. 1995 , Wang et al. 2002 . In this context, the anti-proliferative effect of DRD2 in adrenal glomerulosa cells probably resulted from the attenuation of PKCm and ERK1/2 phosphorylation.
Some may argue that the rennin-angiotensin system is blunt in primary aldosteronism and therefore the exploration of the role of DRD2 in the proliferogenic response to AII is odd. Although the RAS activity may be lower in PA, the AII-responsive subtype of APA is well documented (Gordon 1995) and characterized by an increase in aldosterone secretion on assuming an upright posture and after ambulation. Our previous study has shown an inverse correlation of DRD2 level in APA with PAC and CYP11B2 mRNA expression. This finding indicates that the different amount of DRD2 may contribute to the heterogeneous sensitivity to AII stimulation in APA (Chang et al. 2007) . It is possible that downregulation of DRD2 may increase the sensitivity of the proliferation response to aldosterone-producing cells under the same plasma concentration of AII. As the tumor grew and plasma aldosterone increased, AII decreased in some of these patients, but not all. The reduced AII stimulation slows the tumor growth rate to a steady-state condition. Besides, the AT1R level is not reduced in APA (Chang et al. 2007 ) and some of APA patients do not have reduced plasma AII levels. Therefore, AII could retain its stimulating effect on the proliferation of these aldosterone-producing cells.
In summary, similar to its inhibition aldosterone synthesis/production, DRD2 also antagonizes the AII proliferating effect of adrenal glomerulosa cells as well as APA. PKCm and ERK1/2 are the main signaling pathways mediating this anti-proliferative effect. Our findings provide a new therapeutic target for the medical treatment of human APA and perhaps other types of primary aldosteronism. Effects of DRD2 agonist/antagonist (a), depletion of PKCm (b), and PD98059 treatment (c) on AII-stimulated cyclin D1 expression in primary cultured human adrenal cortical cells. C, control; BMC, 1 mM bromocriptine; Racl, 1 mM raclopride; AII, 10 nM angiotensin II. *P!0.05 vs AII. All experiments were performed in at least triplicate.
